United StatesÚltimas notícias

BrainsWay (NASDAQ:BWAY) reported positive real-world data from what it described as the largest analysis of Deep Transcranial Magnetic Stimulation in patients with comorbid post-traumatic stress disorder and major depressive disorder.

Zentek (NASDAQ:ZTEK) said it has secured a pathway to sell its ZenGUARD enhanced air filtration media in the United States through an exclusive eight-year licensing agreement with Applied Silver.

Alicia Levine, chief investment officer at BNY Wealth, expects an upswing in volatility over the next few months, but sees a broadening of earnings driving the S&P 500 to 8,000 by the end of the year.

Roadzen (NASDAQ:RDZN) reported its best quarter and fiscal year with fourth quarter revenue of $16.1 million, up 42% year over year and 12% sequentially.

Tonix Pharmaceuticals (NASDAQ:TNXP) said it enrolled the first patient in HORIZON, a Phase 2, randomized, double-blind, placebo-controlled study of TNX-102 SL 5.6 mg for adults with major depressive disorder.

HP (NYSE:HPQ) announced a strategic partnership with OpenAI to deploy its Frontier enterprise AI platform across HP’s global business operations.

Artivion (NYSE:AORT) announced that the U.S. Food and Drug Administration has granted premarket approval for its AMDS Hybrid Prosthesis for the treatment of acute DeBakey Type I aortic dissections with malperfusion.

Helus Pharma (NASDAQ:HELP) reported fiscal 2026 results with cash of $157.3 million as of March 31, 2026.

Neurogene (NASDAQ:NGNE) reported updated Phase 1/2 clinical data showing 47 total developmental milestone gains across 10 participants treated with NGN-401 gene therapy for Rett syndrome.

Martin Marietta (NYSE:MLM) said it will combine with Lhoist North America in a transaction valued at about $13.5 billion, structured as a mix of cash and stock consideration.

Rocket Lab (NASDAQ:RKLB) agreed to acquire Iridium (NASDAQ:IRDM) in a transaction valuing the combined deal at about $8 billion enterprise value, combining cash, stock, and structured consideration for shareholders.

Talawar Therapeutics and JATT II (NASDAQ:JATT) have entered into a definitive business combination agreement to create a Nasdaq-listed biotechnology company expected to trade as TLWR in the second half of 2026.